García-Perdomo HA, Pineda-Cañar CA

Idioma: Ingles.
Referencias bibliográficas: 5
Paginas:
Archivo PDF: 172.27 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ramírez-Sevilla C, Gómez-Lanza E, Puyol-Pallàs J-M. Behavior of MV140 vaccine toprevent recurrent urinary tract infectionsin patients with metabolic syndrome andsmoking. Revista Mexicana de Urología. 2022;82(6):1–8. doi: https://doi.org/10.48193/revistamexicanadeurologa.v82i6.959

2. He Q, Wang Z, Liu G, Daneshgari F, MacLennanGT, Gupta S. Metabolic syndrome, inflammationand lower urinary tract symptoms: possibletranslational links. Prostate Cancer Prostatic Dis.2016;19(1):7–13. doi: https://doi.org/10.1038/pcan.2015.43

3. Dobrowolski P, Prejbisz A, Kuryłowicz A, BaskaA, Burchardt P, Chlebus K, et al. Metabolicsyndrome – a new definition and managementguidelines. A joint position paper by the PolishSociety of Hypertension, Polish Society for theTreatment of Obesity, Polish Lipid Association,Polish Association for Study of Liver, PolishSociety of Family Medicine, Polish Society ofLifestyle Medicine, Division of Prevention andEpidemiology Polish Cardiac Society, “Club 30”Polish Cardiac Society, and Division of Metabolicand Bariatric Surgery Society of Polish Surgeons.Arch Med Sci. 2022;18(5):1133–56. doi: https://doi.org/10.5114/aoms/152921

4. Clarke GM, Conti S, Wolters AT, Steventon A.Evaluating the impact of healthcare interventionsusing routine data. BMJ. 2019;365:l2239. doi:https://doi.org/10.1136/bmj.l2239

5. Every-Palmer S, Howick J. How evidencebasedmedicine is failing due to biased trialsand selective publication. Journal of Evaluationin Clinical Practice. 2014;20(6):908–14. doi:https://doi.org/10.1111/jep.12147